Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection

Circulation

Volumn 104, Issue 20, 2001, Pages 2436-2441

  Grube, Eberhard ^a   Gerckens, Ulrich ^a   Yeung, Alan C ^b   Rowold, Sascha ^a   Kirchhof, Nicole ^c   Sedgewick, Jerry ^c   Yadav, Jay S ^d   Stertzer, Simon ^b  

^a Heart Center Siegburg   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angioplasty; Embolism; Grafting

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; HEPARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FILTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL INSTRUMENTATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0035856529     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4501.099317     Document Type: Article

References (25)

1. Thromboembolic complications of coronary angioplasty
2. Embolization complicating coronary angioplasty in the presence of an intracoronary thrombus
3. Thromboembolic complications of percutaneous transluminal coronary angioplasty for myocardial infarction
4. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial
5. Reduced distal embolization with transluminal extraction atherectomy compared to balloon angioplasty for saphenous vein graft disease
6. Clinical implications of the 'no reflow' phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction
7. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction
8. Improved short-term outcomes of primary coronary stenting compared to primary balloon angioplasty in acute myocardial infarction at experienced centers: The PAMI study group experience
9. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: Intravascular ultrasound study of 2256 patients
10. Aortocoronary saphenous vein bypass grafts: Long-term patency, morphology and blood flow in patients with patent grafts early after surgery
11. Aortocoronary saphenous vein bypass grafts
12. Patency of saphenous vein grafts five or more years after coronary bypass surgery
13. Reoperation for coronary artery disease; 18 years of clinical follow up
14. Prolonged infusion of urokinase for re-canalization of chronically occluded aortocoronary bypass grafts
15. Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts
16. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions
17. Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions
18. Laserangioplastie und rekanalisation
19. Percutaneous transluminal therapy of occluded saphenous vein grafts: Can the challenge be met with ultrasound thrombolysis?
20. Results of the VeGAS 1 pilot study of the possis coronary AngioJet thrombectomy catheter
21. Treatment of thrombus containing lesions in diseased native coronary arteries and saphenous vein bypass grafts using the AngioJet Rapid Thrombectomy System
22. Prevention of distal embolization during saphenous vein graft lesion angioplasty: Experience with a new temporary occlusion and aspiration system
23. The SAFE study: Multicenter evaluation of a protection catheter system for distal embolization in coronary venous bypass grafts (SVGs)
24. Effect of platelet gycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts: EPIC investigators (Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in preventing ischemic complications)
25. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial: EPISTENT investigators (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting)